| Zacks Company Profile for Verastem, Inc. (VSTM : NSDQ) |
|
|
| |
| • Company Description |
| Verastem, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing drugs to improve outcomes for patients with cancer. Its programs target the focal adhesion kinase (FAK) and the phosphoinositide 3-kinase (PI3K)/mTOR signaling pathways. Its lead FAK inhibitor is defactinib (VS-6063), an orally available candidate for combination therapy with immuno-oncology agents and other anti-cancer compounds. The company's defactinib is in Phase 1b study for the treatment of pancreatic cancer, as well as in Phase 1/2 clinical trial for the treatment of ovarian cancer, non-small cell lung cancer, mesothelioma, and pancreatic cancer. It also engages in developing duvelisib, an investigational oral therapy that targets the PI3K signaling pathway, as well as attacks malignant B-cells and T-cells and disrupt the tumor microenvironment to help thwart their growth and proliferation for patients with lymphatic cancers through the dual inhibition of PI3K delta and gamma.
Number of Employees: 78 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $7.72 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 1,521,120 shares |
| Shares Outstanding: 66.78 (millions) |
| Market Capitalization: $515.51 (millions) |
| Beta: 0.44 |
| 52 Week High: $11.25 |
| 52 Week Low: $4.01 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-27.17% |
-27.05% |
| 12 Week |
-16.45% |
-17.80% |
| Year To Date |
0.00% |
0.00% |
|
|
|
|
| |
|
|
| |
| • General Corporate Information |
Officers
Daniel W. Paterson - President and Chief Executive Officer
Matthew E. Ros - Chief Operating Officer
Daniel Calkins - Chief Financial Officer
Paul Bunn - Director
Robert Gagnon - Director
|
|
Peer Information
Verastem, Inc. (CORR.)
Verastem, Inc. (RSPI)
Verastem, Inc. (CGXP)
Verastem, Inc. (BGEN)
Verastem, Inc. (GTBP)
Verastem, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 92337C203
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 03/19/26
|
|
Share - Related Items
Shares Outstanding: 66.78
Most Recent Split Date: 6.00 (0.08:1)
Beta: 0.44
Market Capitalization: $515.51 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $-0.63 |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-2.17 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 3.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 03/19/26 |
|
|
|
| |
